Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
Journal of Geriatric Oncology|October 30, 2021
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT studyGerardo Rosati, Domenico Corsi, Antonio Avallone, et al.Tumori|June 29, 2002
"Misura" project: a retrospective survey on the use of 5fluorouracil in the treatment of colorectal cancer in 24 Italian clinical centersPaola Poletti, Graziella Pinotti, Gerardo Rosati, et al.Anticancer Research|April 12, 2015
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian StudyStefania Eufemia Lutrino, Francesca Bergamo, Marta Schirripa, et al.Journal of Geriatric Oncology|February 14, 2018
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr studyGerardo Rosati, Carmine Pinto, Francesca Di Fabio, et al.Oncotarget|August 20, 2016
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectivesValentina Fanotto, Elena Ongaro, Karim Rihawi, et al.European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.The Oncologist|March 11, 2018
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)Carmine Pinto, Maurizio Di Bisceglie, Francesca Di Fabio, et al.British Journal of Cancer|September 20, 2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trialRiccardo Giampieri, Marco Puzzoni, Bruno Daniele, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.Journal of Geriatric Oncology|December 16, 2018
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyValentina Fanotto, Lorenzo Fornaro, Roberto Bordonaro, et al.Pageof 9